Fig. 4: Immune responses to FEN-CRM197 can be generated by sublingual or intranasal booster immunizations containing either dmLT or LTA1 adjuvants. | npj Vaccines

Fig. 4: Immune responses to FEN-CRM197 can be generated by sublingual or intranasal booster immunizations containing either dmLT or LTA1 adjuvants.

From: Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge

Fig. 4

Groups of Balb/c mice (n = 6) were left naïve or primed by 5 μg FEN-CRM ± 0.1 μg of dmLT or 5 μg of LTA1 by IM delivery. Mice were boosted mucosally on weeks 3 and 6 with 9–10 μg FEN-CRM ± 5 μg dmLT SL or 9 μg FEN-CRM ± 5 μg LTA1 IN, both in 30 μl. On week 8, serum and bone-marrow were collected for immune response evaluation. a Schematic of immunization schedule. b Compiled serum anti-CRM and anti-FEN (FEN-BSA, FEN-TT) serum IgG ELISAs. c Compiled serum anti-FEN (FEN-TT) serum IgG1 or IgG2a ELISAs. d Representative anti-FEN (TT-BSA coated) IgG/IgA ELISPOT images from bone-marrow. Blue spots indicate IgG and red spots IgA ASCs. d Compiled serum anti-FEN (FEN-BSA) IgA ELISA. e Compiled anti-FEN IgG ASC per 106 cells from bone-marrow. Bars at mean + s.e.m. with significance determined by ANOVA paired with Bonferroni post-hoc test as shown (*P < 0.05, **P < 0.01, ***P < 0.001).

Back to article page